Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Swedish Biomimetics 3000
London, England, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
Swedish Biomimetics 3000 developed μLOT, a novel continuous manufacturing process for therapeutic peptides. This platform enables in-line process analytical technologies throughout production, improving quality control and reducing costs. The approach aims to disrupt traditional batch peptide synthesis by offering greener, more efficient production with broad applicability across the pharmaceutical industry. No clinical results reported as it is not a therapeutics developer.[5][6][7]
- Modalities
- Peptides
- Industry
- Contract Manufacturing Organization
Beyond the preview
Go deeper on Swedish Biomimetics 3000.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Swedish Biomimetics 3000.